Unifuzol® in Patients With Peripheral Arterial Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT03861416

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company (from the registry)
Registry
  • NCT NCT03861416
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03861416. Randomized; double masking; primary purpose treatment. Start 2018-03-16 (actual); primary completion 2019-09-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
"Unifuzol®" in Patients With Peripheral Arterial Disease
Condition
Peripheral Arterial Disease
Intervention (Drug)
L-arginine 1.4% 500 ml
Intervention (Drug)
L-arginine 1.4% 250 ml + placebo 250 ml
Intervention (Drug)
Placebo solution
Lead sponsor
POLYSAN Scientific & Technological Pharmaceutical Company (class: industry)

Record details

Record id
cardio:ct-nct03861416
Content hash
98b154916b48c57845937b28b888f6267adb3969d0d1da683d6f774e1826df68